J Drugs Dermatol. 2022 Jun 1;21(6):637-644. doi: 10.36849/JDD.6237.
Studies have proposed a link between psoriasis and imbalanced gut microbiome. Therefore, the modulation of the gut microbiota with probiotics may improve clinical outcomes, chronic inflammation, and cardiovascular risk factors in patients with psoriasis.
In a randomized double-blind placebo-controlled clinical trial, forty-six patients with psoriasis randomly assigned into probiotic capsules contains multi-strain at least 1.6× 109 CFU/g bacteria or placebo for two months. Psoriasis Area and Severity Index (PASI), blood pressure, quality of life (QOL) pro-inflammatory cytokines (hs-CRP and IL1-β), and lipopolysaccharides (LPS) were measured.
Improvements in QOL was significant in patients taking probiotics supplementation comparing to the placebo group and PASI (-5.06±2.10 vs 0.30±1.80, P=0.049) as well. After the intervention, a considerable reduction in serum LPS levels (-7.21±10.33 vs -2.74±0.97 mmol/L, P=0.010), hs-CRP levels (-1.67±0.95 vs -0.70+ 0.38 mg/L, P=0.013), and IL1- β levels (-1.64±1.10 vs 0.17+ -0.20 mg/L, P=0.043) in the probiotics group.
This study shows that probiotics significantly improved the quality of life and seriousness in psoriatic patients. Moreover, it enhances cardiovascular risk factors and inflammatory/oxidative stress markers.
This trial also was recorded in the Iranian registry of clinical trials (https://www.irct.ir) (code: IRCT20191124045483N1). J Drugs Dermatol. 2022;21(6):637-644. doi:10.36849/JDD.6237.
研究提出银屑病与肠道微生物组失衡之间存在关联。因此，通过益生菌来调节肠道微生物群可能会改善银屑病患者的临床结果、慢性炎症和心血管风险因素。
在一项随机、双盲、安慰剂对照的临床试验中，将 46 名银屑病患者随机分为益生菌胶囊组（至少含有 1.6×109 CFU/g 细菌的多菌株）或安慰剂组，持续两个月。测量银屑病面积和严重程度指数（PASI）、血压、生活质量（QOL）、促炎细胞因子（hs-CRP 和 IL1-β）和脂多糖（LPS）。
与安慰剂组相比，服用益生菌补充剂的患者 QOL 显著改善（+5.06±2.10 与 0.30±1.80，P=0.049），PASI 也显著改善（-5.06±2.10 与 0.30±1.80，P=0.049）。干预后，益生菌组血清 LPS 水平（-7.21±10.33 与 -2.74±0.97 mmol/L，P=0.010）、hs-CRP 水平（-1.67±0.95 与 -0.70+0.38 mg/L，P=0.013）和 IL1-β水平（-1.64±1.10 与 0.17+0.20 mg/L，P=0.043）均显著降低。
本研究表明益生菌可显著改善银屑病患者的生活质量和严重程度，且可改善心血管风险因素和炎症/氧化应激标志物。
本试验也已在伊朗临床试验注册中心（https://www.irct.ir）注册（注册号：IRCT20191124045483N1）。J 皮肤病学杂志。2022；21（6）：637-644。doi:10.36849/JDD.6237.
